Journal of Experimental & Clinical Cancer Research

Journal of Experimental & Clinical Cancer Research (commonly abbreviated as ''J. Exp. Clin. Cancer Res.') is an open-access oncology journal published by BioMed Central. Founded in 1982, it is the official journal of the Regina Elena National Cancer Institute in Rome, and recorded a 2025 impact factor of 14.3.Journal of Experimental & Clinical Cancer Research（常用缩写 J. Exp. Clin. Cancer Res.）是由 BioMed Central 出版的肿瘤学开放获取期刊，创刊于 1982 年，为罗马 Regina Elena 国家癌症研究所的官方刊物，2025 年影响因子为 14.3。^[1]

Scope

• Disciplinary focus: the journal publishes high-quality multidisciplinary research on all aspects of basic, clinical and translational oncology, providing a resource for oncologists and researchers alike. It ranks in the first quartile of the oncology category in the Journal Citation Reports.学科定位： 刊发肿瘤学基础、临床与转化研究各方面的高质量多学科成果，为肿瘤科医师与研究者提供交流平台，在期刊引证报告中列肿瘤学类别第一分区。
• Readership: the journal reaches oncology institutes and universities worldwide, and the great majority of articles submitted and published in recent years have come from international oncology institutes and universities.读者： 读者覆盖全球的肿瘤研究机构与高校，该刊近年绝大部分投稿与刊文来自世界各地的肿瘤研究所与大学。
• Scope of contributions: the journal covers the biological, epidemiological, immunological, pathological, radiobiological and clinical aspects of oncology, with topics ranging from molecular genetics through infectious agents to surgery and therapeutic approaches and outcomes.收稿范围： 涵盖肿瘤学的生物学、流行病学、免疫学、病理学、放射生物学与临床各层面，研究主题从分子遗传学经由感染性病因延伸至外科与治疗手段及其结局。
• Reviews and guidelines: drawing on its editors' experience in evaluating and conducting systematic reviews and in developing clinical practice guidelines, the journal is an attractive forum for reviews and guidelines, and it establishes specialist sections under expert section editors as needs arise.综述与指南： 依托编委在评价系统综述与制定临床实践指南方面的经验，期刊成为发表综述与指南的常用论坛，并按需设立由专家编辑主持的专题栏目。
• Open access: the journal is fully open access and publishes articles online immediately upon acceptance, with a median of 3 days from submission to first decision and 17 days from acceptance to publication.开放获取： 完全开放获取，文章录用后立即在线发表，投稿至首次决定的中位时长为 3 天，录用至发表的中位时长为 17 天。^[2]

History

• 1982: the journal was founded as a quarterly, initially printed in Rome and issued in physical form. The print collection covering 1982 to 2007 is now preserved in the Institute's library.1982年： 期刊创刊，为季刊，最初由罗马的一家出版机构承印，早期以印刷形态发行，1982 年至 2007 年的纸本收藏如今保存在研究所的图书馆内。
• From 1986: the journal became the official scientific journal of the Regina Elena National Cancer Institute, taking on the role of a translational bridge between the laboratory and the clinic.1986年起： 成为 Regina Elena 国家癌症研究所的官方科学刊物，承担连接实验室与临床的转化桥梁角色。
• From 1999: an online archive was established and digitisation of the back numbers began, laying the groundwork for the journal's later move to full online publication.1999年起： 设立在线档案，早年卷次的数字化回溯由此展开，为后续全面网络化打下基础。
• 2008: the journal moved to the BioMed Central open-access publishing platform and became a fully open-access journal. Its inaugural Editor-in-Chief, Mauro Castelli, set out the reasons for the change in an editorial, noting that the online archive would remain available back to 1999.2008年： 迁入 BioMed Central 的开放获取出版平台，成为完全开放获取期刊，创任主编 Mauro Castelli 撰文说明这一转变，主机归档可回溯至 1999 年。
• The 2010s to the 2020s: the impact factor rose from below 1 in the early 2000s to 12.658 in 2021, then to 12.8 in 2024 and 14.3 in 2025, confirming the journal's position near the top of the international oncology titles.2010年代至2020年代： 影响因子由 2000 年代初期的不足 1 升至 2021 年的 12.658，再到 2024 年的 12.8 与 2025 年的 14.3，在国际肿瘤学期刊中稳居第一分区前列。^[3]

Editors

• Editor-in-Chief: the journal is led by Mauro Castelli at the Regina Elena National Cancer Institute in Rome, who is also the Institute's scientific director.主编： 现任主编为 Mauro Castelli 博士，任职于罗马 Regina Elena 国家癌症研究所，即该研究所的科学总监。
• Deputy Editor and staff: Giovanni Blandino serves as Deputy Editor, with Assistant Editors including Silvia Di Agostino and Sara Donzelli, and Alice Castelli as Managing Editor for day-to-day editorial business.副主编与编辑职员： 副主编为 Giovanni Blandino，助理编辑包括 Silvia Di Agostino 与 Sara Donzelli，另设执行编辑 Alice Castelli 负责日常编辑事务。
• International board: the board is made up of highly qualified international experts from institutions including the MD Anderson Cancer Center at the University of Texas and Tsinghua University, and the journal asks that studies present unpublished findings in multiple models with non-incremental conclusions and clear clinical relevance.国际编委： 编委由国际知名的肿瘤学专家组成，来自德克萨斯大学 MD 安德森癌症中心、清华大学等机构，评审环节强调研究须在多个模型上呈现未发表的发现并具备明确的临床关联。
• Submission system: manuscripts are submitted through the online system of Springer Nature, the journal runs themed calls for papers as curated Collections, and it also shares its latest articles and Collections on social media.投稿系统： 稿件经施普林格自然旗下的在线投稿系统提交，期刊另以专辑形式接受专题征稿，并已在社交媒体上同步发布最新文章与专辑动态。^[4]